1 / 6

Progressive Pulmonary Fibrosis Market

DelveInsight's "Progressive Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Progressive Pulmonary Fibrosis, historical and forecasted epidemiology, and the Progressive Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<br>

PharmaInsights
Download Presentation

Progressive Pulmonary Fibrosis Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Progressive Pulmonary Fibrosis Market Report 2032 | DelveInsight DelveInsight's "Progressive Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Progressive Pulmonary Fibrosis, historical and forecasted epidemiology, and the Progressive Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Progressive Pulmonary Fibrosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Progressive Pulmonary Fibrosis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Progressive Pulmonary Fibrosis treatment practice/algorithms, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Progressive Pulmonary Fibrosis market. Progressive Pulmonary Fibrosis: An Overview

  2. Progressive pulmonary fibrosis (PPF) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality. Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto- immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible. Progressive pulmonary fibrosis (PPF) are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The type-specific segmentation majorly includes, Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs. Learn about Progressive Pulmonary Fibrosis, different geographies treatment algorithms, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/progressive-pulmonary- fibrosis-ppf-market Progressive Pulmonary Fibrosis Market Progressive pulmonary fibrosis (PPF) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality. ILD and its progressing forms, form a substantial proportion of disabling chronic lung disease leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the

  3. chronic fibrotic ILDs in the 7MM. Myriads of patients with PPFs are currently orphan of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes and are the mainstay of treatment in PPFs. These unmet treatment gaps accentuates the launch of emerging therapies. In the upcoming treatment landscape, there are plethora of companies investigating agents for use in the PPF which includes Boehringer Ingelheim, Bristol- Myers Squibb, FibroGen, Hoffmann-La Roche Ltd., Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB. There are many more pharma companies which are conducting clinical trials for therapies of PPF. Progressive Pulmonary Fibrosis Market Insights: ●The therapeutic market size of Progressive pulmonary fibrosis (PPF) in the 7MM was USD 891 million in 2021. ●The United States accounts for the highest market size of Progressive pulmonary fibrosis (PPF) approximately 77% of the total market size in 7MM in 2021, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Request a sample and discover more about the report offerings at: https://www.delveinsight.com/sample-request/progressive-pulmonary- fibrosis-ppf-market Progressive Pulmonary Fibrosis Epidemiology The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Progressive pulmonary fibrosis (PPF) in the 7MM

  4. covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032. Progressive Pulmonary Fibrosis Epidemiology Insights ●In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) in the 7MM were 127,754 in 2021. ●The highest total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) were accounted by the US in 2021 (71,657 cases), which are expected to show a rise in the future. Progressive Pulmonary Fibrosis Therapeutics Assessment Major key companies such as Boehringer Ingelheim, and others are working proactively in the Progressive Pulmonary Fibrosis Therapeutics market to develop novel therapies which will drive the Progressive Pulmonary Fibrosis treatment market in the upcoming years. Progressive Pulmonary Fibrosis Report Key Insights 1. Progressive Pulmonary Fibrosis Patient Population 2. Progressive Pulmonary Fibrosis Market Size and Trends 3. Key Cross Competition in the Progressive Pulmonary Fibrosis Market 4. Progressive Pulmonary Fibrosis Market Dynamics (Key Drivers and Barriers) 5. Progressive Pulmonary Fibrosis Market Opportunities 6. Progressive Pulmonary Fibrosis Therapeutic Approaches 7. Progressive Pulmonary Fibrosis Pipeline Analysis 8. Progressive Pulmonary Fibrosis Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Progressive Pulmonary Fibrosis Market Table of Contents

  5. 1. Key Insights 2. Executive Summary 3. Progressive Pulmonary Fibrosis Competitive Intelligence Analysis 4. Progressive Pulmonary Fibrosis Market Overview at a Glance 5. Progressive Pulmonary Fibrosis Disease Background and Overview 6. Progressive Pulmonary Fibrosis Patient Journey 7. Progressive Pulmonary Fibrosis Epidemiology and Patient Population 8. Progressive Pulmonary Fibrosis Treatment Algorithm, Current Treatment, and Medical Practices 9. Progressive Pulmonary Fibrosis Unmet Needs 10. Key Endpoints of Progressive Pulmonary Fibrosis Treatment 11. Progressive Pulmonary Fibrosis Marketed Products 12. Progressive Pulmonary Fibrosis Emerging Therapies 13. Progressive Pulmonary Fibrosis Seven Major Market Analysis 14. Attribute Analysis 15. Progressive Pulmonary Fibrosis Market Outlook (7 major markets) 16. Progressive Pulmonary Fibrosis Access and Reimbursement Overview 17. KOL Views on the Progressive Pulmonary Fibrosis Market 18. Progressive Pulmonary Fibrosis Market Drivers 19. Progressive Pulmonary Fibrosis Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer Get the Detailed TOC of the Progressive Pulmonary Fibrosis Market report here: https://www.delveinsight.com/report-store/progressive-pulmonary-fibrosis- ppf-market About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

  6. Contact Us: Kritika Rehani krehani@delveinsight.com info@delveinsight.com +1(919)321-6187 www.delveinsight.com

More Related